Abstract
Background
For many people living with HIV (PLWH), taking antiretroviral therapy (ARV) every day is difficult.
Methods
Average adherence (Av-Adh) and log-transformed treatment interruption (TI) to ARV were prospectively measured over 6 months using electronic drug monitoring (EDM) in several cohorts of PLWH. Multivariate linear regression models including baseline confounders explored the influence of EDM-defined adherence (R 2) on 6-month Log10 HIV-RNA. Multivariate logistic regression models were used to compare the risk of HIV-RNA detection within subgroups stratified by lower (≤95%) and higher (>95%) Av-Adh.
Results
Three hundred ninety nine PLWH were analyzed with different ARV: dolutegravir (n=102), raltegravir (n=90), boosted PI (bPI; n=107), and NNRTI (n=100). In the dolutegravir group, the influence of adherence pattern measures on R 2 for HIV-RNA levels was marginal (+2%). Av-Adh, TI and Av-Adh x TI increased the R 2 for HIV-RNA levels by 54% and 40% in the raltegravir and bPI treatment groups, respectively. TI increased the R 2 for HIV-RNA levels by 36% in the NNRTI treatment group. Compared to dolutegravir-based regimen, the risk of VR was significantly increased for: raltegravir (adjusted OR (aOR), 45.6; 95% confidence interval (CI) [4.5 - 462.1], p=0.001); NNRTIs (aOR, 24.8; 95% CI [2.7 - 228.4], p=0.005) and bPIs (aOR, 28.3; 95%CI [3.4 - 239.4], p=0.002) in PLWH with Av-Adh ≤95%. Among PLWH with >95% Av-Adh, there were no significant differences on the risk of VR among the different ARV.
Conclusion
These findings support the concept that dolutegravir in combination with two other active ARVs achieves a greater virological suppression than older ARV, including raltegravir, NNRTI and bPI among PLWH with lower adherence.